Recruiting NA Multiple Sclerosis

New treatment option for Multiple Sclerosis

Official title Intermittent Hypoxia in Persons With Multiple Sclerosis

ClinicalTrials.gov ID: NCT06276634

What this study is testing

What it's testing
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 75

You may be able to join if

  • Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS)
  • Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5
  • Motor Functional System Scale (FSS) between 2-4
  • Relapse free for at least 1 year
  • Age ≥ 18 years and ≤ 75 years

You likely can't join if

  • Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan
  • Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55)
  • History of epilepsy
  • Chronic obstructive pulmonary disease
  • Uncontrolled Sleep apnea
  • Pregnancy
See the full eligibility criteria
Who can join
  • Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS)
  • Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5
  • Motor Functional System Scale (FSS) between 2-4
  • Relapse free for at least 1 year
  • Age ≥ 18 years and ≤ 75 years
  • Safe to be scanned based on MRI questionnaire
  • Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening
What rules you out
  • Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan
  • Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55)
  • History of epilepsy
  • Chronic obstructive pulmonary disease
  • Uncontrolled Sleep apnea
  • Pregnancy

The study team makes the final eligibility decision.

Where it's taking place

  • Chicago, Illinois, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Chicago, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.